1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1.Drivers
3.2.2.Restraints
3.2.3.Opportunities
3.2.4.Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for the United States Blood Cancer Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in the United States Blood Cancer Drugs Market
4. United States Blood Cancer Drugs
Market by Product
4.1. Rituaxan/Mabthera
4.2. Gleevac/Glivec
4.3. Revlimid
4.4. Velcade
4.5. Tasigna
4.6. Pomalyst
4.7. Vidaza
4.8. Others
5. United States Blood Cancer Drugs
Market by Treatment Approach
5.1. Chemotherapeutic
5.2. Targeted Therapies
5.3. Immunotherapeutic
6. United States Blood Cancer Drugs
Market by Application
6.1. Leukemia
6.2. Lymphoma
6.3. Multiple Myeloma
7. Company Profiles
7.1. Company 1
7.2. Company 2
7.3. Company 3
7.4. Company 4
7.5. Company 5
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1.Drivers
3.2.2.Restraints
3.2.3.Opportunities
3.2.4.Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for the United States Blood Cancer Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in the United States Blood Cancer Drugs Market
4. United States Blood Cancer Drugs
Market by Product
4.1. Rituaxan/Mabthera
4.2. Gleevac/Glivec
4.3. Revlimid
4.4. Velcade
4.5. Tasigna
4.6. Pomalyst
4.7. Vidaza
4.8. Others
5. United States Blood Cancer Drugs
Market by Treatment Approach
5.1. Chemotherapeutic
5.2. Targeted Therapies
5.3. Immunotherapeutic
6. United States Blood Cancer Drugs
Market by Application
6.1. Leukemia
6.2. Lymphoma
6.3. Multiple Myeloma
7. Company Profiles
7.1. Company 1
7.2. Company 2
7.3. Company 3
7.4. Company 4
7.5. Company 5